GA
UTHR icon

Greenspring Advisors’s United Therapeutics UTHR Stock Holding History

Greenspring Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
411
+12
+3% +$6.76K 0.01% 315
2026
Q1 		$237K Buy
+399
New +$199K 0.01% 282

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Greenspring Advisors's UTHR Position: Q2 2026 in Review

Greenspring Advisors increased its United Therapeutics (UTHR) stake by 3% in Q2 2026, buying an estimated $6.76K and bringing the position to 411 shares worth $223K. The position accounts for 0.01% of the portfolio, ranked #315.

Greenspring Advisors first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $237K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Greenspring Advisors held 411 shares of United Therapeutics worth $223K as of Q2 2026.
  • Greenspring Advisors bought 12 United Therapeutics shares in Q2 2026, an estimated $6.76K.
  • United Therapeutics made up 0.01% of Greenspring Advisors's portfolio in Q2 2026, its #315 holding.
  • Greenspring Advisors first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Greenspring Advisors's United Therapeutics position peaked at $237K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Greenspring Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.